Metastatic Rhabdomyosarcoma: A Retrospective Review of Patients Treated at the Hospital for Sick Children between 1989 and 1999

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 4, 2004, Pages 243-247

  Williams, Brent A ^a   Williams, Kelly M ^a   Doyle, John ^a   Stephens, Derek ^a   Greenberg, Mark ^a   Malkin, David ^a   Pappo, Alberto S ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bone marrow transplant; Retrospective analysis; Rhabdomyosarcoma; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOSARCOMA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; ONTARIO; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 16544372880     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200404000-00006     Document Type: Review

References (12)

1. Kramer S, Meadows AT, Jarrett P, et al. Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst. 1983;70:49.
2. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study I: a final report. Cancer. 1988;61:209-220.
3. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study II. Cancer. 1993;71:1904-1922.
4. Crist W, Gehan EA, Ragab AH, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
5. Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol. 2001;37:442-448.
6. Pappo AS, Lyden E, Breneman J, et al. Up front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 2001;19:213-219.
7. Weigel BJ, Breitfeld PP, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001;23:266-267.
8. Maurer HM, Moon T, Donaldson M, et al. The Intergroup Rhabdomyosarcoma Study: A preliminary report. Cancer. 1977;40:2015-2026.
9. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003;21:78-84.
10. Koscielniak E, Rodary C, Flamant F, et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: A retrospective European multicenter analysis. Med Pediatr Oncol. 1992;20:209-214.
11. Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol. 2001;23:225-233.
12. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol. 1999;17:2796-2803.